@article{AlterOttvonWebskyetal.2012,
  author    = {Alter, Markus L. and Ott, Ina M. and von Websky, Karoline and Tsuprykov, Oleg and Sharkovska, Yuliya and Krause-Relle, Katharina and Raila, Jens and Henze, Andrea and Klein, Thomas and Hocher, Berthold},
  title     = {DPP-4 Inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy},
  series = {Kidney \& blood pressure research : official organ of the Gesellschaft f{\"u}r Nephrologie},
  volume    = {36},
  journal   = {Kidney \& blood pressure research : official organ of the Gesellschaft f{\"u}r Nephrologie},
  number    = {1},
  publisher = {Karger},
  address   = {Basel},
  issn      = {1420-4096},
  doi       = {10.1159/000341487},
  pages     = {119 -- 130},
  year      = {2012},
  abstract  = {Background: The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). This study investigated the effect of the novel dipeptidyl peptidase-4 inhibitor linagliptin alone and in combination with the ARB telmisartan on the progression of diabetic nephropathy in diabetic endothelial nitric oxide synthase (eNOS) knockout mice. Methods: Sixty male eNOS knockout C57BL/6J mice were divided into four groups after receiving intraperitoneal high-dose streptozotocin: telmisartan (1 mg/kg), linagliptin (3 mg/kg), linagliptin + telmisartan (3 mg/kg + 1 mg/kg) and vehicle. Fourteen mice were used as non-diabetic controls. Results: After 12 weeks, urine and blood were obtained and blood pressure measured. Glucose concentrations were increased and similar in all diabetic groups. Telmisartan alone reduced systolic blood pressure by 5.9 mmHg versus diabetic controls (111.2 +/- 2.3 mmHg vs 117.1 +/- 2.2 mmHg; mean +/- SEM; P = 0.071). Combined treatment significantly reduced albuminuria compared with diabetic controls (71.7 +/- 15.3 mu g/24 h vs 170.8 +/- 34.2 mu g/24 h; P = 0.017), whereas the effects of single treatment with either telmisartan (97.8 +/- 26.4 mu g/24 h) or linagliptin (120.8 +/- 37.7 mu g/24 h) were not statistically significant. DPP-4 inhibition, alone and in combination, led to significantly lower plasma osteopontin levels compared with telmisartan alone. Histological analysis revealed reduced glomerulosclerosis after Linagliptin alone and in combination with telmisartan in comparison to non treated diabetic animals (p < 0.01 and p < 0.05). Kidney malonaldehyde immune-reactivity, a marker of oxidative stress, was significantly lower in animals treated with linagliptin. Conclusions: DPP-4 inhibition on top of ARB treatment significantly reduced urinary albumin excretion and oxidative stress in diabetic eNOS knockout mice. Linagliptin on top of an angiotensin II receptor blocker may offer a new therapeutic approach for patients with diabetic nephropathy.},
  language  = {en}
}
@article{KieferKrahlOsthoffetal.2017,
  author    = {Kiefer, Thomas and Krahl, Dorothea and Osthoff, Kathrin and Thuss-Patience, Peter and Bunse, J{\"o}rg and Adam, Ulrich and Jansen, Marc H. and Ott, Rudolf and Pfitzmann, Robert and Pross, Matthias and Kohlmann, Thomas and Daeschlein, Georg and Buhlert, Hermann and V{\"o}ller, Heinz and Hirt, Carsten},
  title     = {Importance of Pancreatic Enzyme Replacement Therapy after Surgery of Cancer of the Esophagus or the Esophagogastric Junction},
  series = {Nutrition and cancer : an international journal},
  volume    = {70},
  journal   = {Nutrition and cancer : an international journal},
  number    = {1},
  publisher = {Routledge, Taylor \& Francis Group},
  address   = {Abingdon},
  issn      = {0163-5581},
  doi       = {10.1080/01635581.2017.1374419},
  pages     = {69 -- 72},
  year      = {2017},
  abstract  = {After surgical treatment of cancer of the esophagus or the esophagogastric junction we observed steatorrhea, which is so far seldom reported. We analyzed all patients treated in our rehabilitation clinic between 2011 and 2014 and focused on the impact of surgery on digestion of fat. Reported steatorrhea was anamnestic, no pancreatic function test was made. Here we show the results from 51 patients. Twenty-three (45\%) of the patients reported steatorrhea. Assuming decreased pancreatic function pancreatic enzyme replacement therapy (PERT) was started or modified during the rehabilitation stay (in the following called STEA(+)). These patients were compared with the patients without steatorrhea and without PERT (STEA(-)). Maximum weight loss between surgery and rehabilitation start was 18 kg in STEA(+) patient and 15.3 kg in STEA(-) patients. STEA(+) patients gained more weight under PERT during the rehabilitation phase (3 wk) than STEA(-) patients without PERT (+1.0 kg vs. -0.3 kg, P = 0.032). We report for the first time, that patients after cancer related esophageal surgery show anamnestic signs of exocrine pancreas insufficiency and need PERT to gain body weight.},
  language  = {en}
}
@article{deVeraBoettgerdelaTorreNoetzeletal.2012,
  author    = {de Vera, Jean-Pierre Paul and B{\"o}ttger, Ute and de la Torre N{\"o}tzel, Rosa and Sanchez, Francisco J. and Grunow, Dana and Schmitz, Nicole and Lange, Caroline and H{\"u}bers, Heinz-Wilhelm and Billi, Daniela and Baque, Mickael and Rettberg, Petra and Rabbow, Elke and Reitz, G{\"u}nther and Berger, Thomas and M{\"o}ller, Ralf and Bohmeier, Maria and Horneck, Gerda and Westall, Frances and J{\"a}nchen, Jochen and Fritz, J{\"o}rg and Meyer, Cornelia and Onofri, Silvano and Selbmann, Laura and Zucconi, Laura and Kozyrovska, Natalia and Leya, Thomas and Foing, Bernard and Demets, Rene and Cockell, Charles S. and Bryce, Casey and Wagner, Dirk and Serrano, Paloma and Edwards, Howell G. M. and Joshi, Jasmin Radha and Huwe, Bj{\"o}rn and Ehrenfreund, Pascale and Elsaesser, Andreas and Ott, Sieglinde and Meessen, Joachim and Feyh, Nina and Szewzyk, Ulrich and Jaumann, Ralf and Spohn, Tilman},
  title     = {Supporting Mars exploration BIOMEX in Low Earth Orbit and further astrobiological studies on the Moon using Raman and PanCam technology},
  series = {Planetary and space science},
  volume    = {74},
  journal   = {Planetary and space science},
  number    = {1},
  publisher = {Elsevier},
  address   = {Oxford},
  issn      = {0032-0633},
  doi       = {10.1016/j.pss.2012.06.010},
  pages     = {103 -- 110},
  year      = {2012},
  abstract  = {The Low Earth Orbit (LEO) experiment Biology and Mars Experiment (BIOMEX) is an interdisciplinary and international space research project selected by ESA. The experiment will be accommodated on the space exposure facility EXPOSE-R2 on the International Space Station (ISS) and is foreseen to be launched in 2013. The prime objective of BIOMEX is to measure to what extent biomolecules, such as pigments and cellular components, are resistant to and able to maintain their stability under space and Mars-like conditions. The results of BIOMEX will be relevant for space proven biosignature definition and for building a biosignature data base (e.g. the proposed creation of an international Raman library). The library will be highly relevant for future space missions such as the search for life on Mars. The secondary scientific objective is to analyze to what extent terrestrial extremophiles are able to survive in space and to determine which interactions between biological samples and selected minerals (including terrestrial, Moon- and Mars analogs) can be observed under space and Mars-like conditions. In this context, the Moon will be an additional platform for performing similar experiments with negligible magnetic shielding and higher solar and galactic irradiation compared to LEO. Using the Moon as an additional astrobiological exposure platform to complement ongoing astrobiological LEO investigations could thus enhance the chances of detecting organic traces of life on Mars. We present a lunar lander mission with two related objectives: a lunar lander equipped with Raman and PanCam instruments which can analyze the lunar surface and survey an astrobiological exposure platform. This dual use of testing mission technology together with geo- and astrobiological analyses will significantly increase the science return, and support the human preparation objectives. It will provide knowledge about the Moon's surface itself and, in addition, monitor the stability of life-markers, such as cells, cell components and pigments, in an extraterrestrial environment with much closer radiation properties to the surface of Mars. The combination of a Raman data base of these data together with data from LEO and space simulation experiments, will lead to further progress on the analysis and interpretation of data that we will obtain from future Moon and Mars exploration missions.},
  language  = {en}
}
@article{vanEgmondFroehlichMoessleAhrensEipperetal.2007,
  author    = {van Egmond-Fr{\"o}hlich, Andreas and M{\"o}ßle, Thomas and Ahrens-Eipper, Sabine and Schmid-Ott, Gerhard and H{\"u}llinghorst, Rolf and Warschburger, Petra},
  title     = {{\"U}berm{\"a}ssiger Medienkonsum von Kindern und Jugendlichen : Risiken f{\"u}r Psyche und K{\"o}rper},
  year      = {2007},
  language  = {de}
}